Meet David Robinson, the OpenAI safety leader who quit and warned that the company isn’t careful enough

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-10-04 • Permanent link

Fractured investor confidence has been exposed in the wake of a disturbing study on glucosamine supplements. The Journal of Alzheimer's Disease recently published research indicating that users are 25% more likely to experience mild cognitive impairment. This alarming finding has sent shockwaves through the health supplement industry, with companies like NOW Foods and Nature's Bounty facing mounting scrutiny. The market has responded with a muted tone, with many investors reevaluating their positions on the sector.

Doubts are growing about the long-term safety of glucosamine supplements, which have long been touted as a natural remedy for joint pain and osteoarthritis. The implications of this study are far-reaching, with potential consequences for consumers who have relied on these products for years. As investors reassess their portfolios, many are wondering whether the benefits of glucosamine supplements outweigh the risks. The answer, it seems, is no longer clear-cut.

Glucosamine supplements have been a staple of the health food industry for decades, with sales reaching an estimated $1.5 billion in 2020 alone. However, the discovery of this potential link to cognitive impairment marks a significant turning point in the industry's history. Many experts argue that the study's findings are a wake-up call for companies to reassess their marketing strategies and product formulations. As the industry grapples with this new reality, it remains to be seen whether glucosamine supplements will continue to be a viable option for consumers.

As the dust settles on this developing story, investors are left to ponder the potential fallout. With many companies facing reputational damage and regulatory scrutiny, it's likely that we'll see a significant shift in consumer behavior in the coming months. On the other hand, some experts argue that the study's findings may ultimately lead to the development of safer, more effective glucosamine supplements. Whatever the outcome, one thing is clear: the glucosamine industry will never be the same again.